Krensavage Asset Management, LLC 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Krensavage Asset Management, LLC disclosed 12 US equity positions worth $169.0m in its Q4 2024 13F filing. The largest position was UTHR at 19.2% of the reported book, followed by EXEL and CAH. Against the Q3 2024 filing, it opened 0 new positions, added to 2 and reduced 10 among the top 12 holdings.
What did Krensavage Asset Management, LLC own in Q4 2024? Top 12 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | UTHR UNITED THERAPEUTICS CORP | Healthcare | 19.2% | $32.5m | 92,057 | -8% | reduced |
| 2 | EXEL EXELIXIS INC | Healthcare | 19.0% | $32.2m | 965,866 | -25% | reduced |
| 3 | CAH CARDINAL HEALTH INC | Healthcare | 14.6% | $24.7m | 208,845 | -1% | reduced |
| 4 | BIIB BIOGEN INC | Healthcare | 9.9% | $16.7m | 108,923 | -4% | reduced |
| 5 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 7.7% | $13.0m | 105,803 | -4% | reduced |
| 6 | ENTA ENANTA PHARMACEUTICALS INC | Healthcare | 7.2% | $12.2m | 2,117,390 | 41% | added |
| 7 | INDIVIOR PLC | 6.9% | $11.6m | 935,680 | 33% | added | |
| 8 | BNTX BIONTECH SE-ADR | Healthcare | 6.0% | $10.1m | 88,663 | -5% | reduced |
| 9 | SNY SANOFI-ADR | 4.3% | $7.2m | 149,196 | -1% | reduced | |
| 10 | ALKS ALKERMES PLC | Healthcare | 4.1% | $6.8m | 238,136 | -5% | reduced |
| 11 | VNDA VANDA PHARMACEUTICALS INC | Healthcare | 1.1% | $1.8m | 378,762 | -9% | reduced |
| 12 | MURAL ONCOLOGY PLC | 0.1% | $226.0k | 70,163 | -8% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.